NEULANDLAB surged +8.0% on a box breakout
Neuland Laboratories closed sharply higher on 6 August, finishing 7.95% above the previous close of ₹19,956.00. The move was made at the open rather than through the day: the stock gapped up 9.24% and pushed to a high of ₹22,490.00, then gave ground, with a low of ₹21,000 and a close of ₹21,543 well below that high. Strota's signals stamped it a gap-and-hold of +9.2% while also flagging the close as 0.59% below the day's volume-weighted average price — buyers set the price early, sellers had the better of the later hours.
Turnover was the other story, and here the pack contradicts itself. The live signal reads a volume spike of 30.7 times; the technicals block reports relative volume of 26.99. Both describe an extraordinary day, but they are not the same figure and the pack does not say which lookback each uses. On the derivatives side there is nothing to work with: the F&O positioning field is null, meaning no futures positioning was captured for the session rather than a reading that came back flat.
The institutional and insider trail is empty rather than missing, which is the more informative of the two. No bulk or block deals were recorded on the day, the 30-day institutional deals list is an empty record, and there are no insider filings in the last 60 days. Whatever moved the stock, the pack shows no disclosed large-ticket buyer or seller behind it.
Technically, this was a stock already extended before the gap. The 14-day RSI sits at 72.7, above the conventional overbought line, and the price is above both its 50-day and 200-day moving averages. A Darvas box breakout — a move clear of a recent tight range — triggered, though the broader trend template screen was not met. The stock is 4.21% below its 52-week high and 87.33% above its 52-week low, with gains of about 12.19% over the past week and 14.05% over the past month, so the jump extended a run already in progress.
The most recent news item in the pack is a GuruFocus report from roughly 15 hours earlier summarising Neuland's Q1 2027 earnings call, its headline citing revenue growth of 116%. That timing fits an overnight repricing, but the pack carries only the headline and not the underlying numbers, so the growth cannot be verified from here. A CNBC TV18 headline from about 85 days ago reported a similar post-results jump alongside a company caution that its numbers can be lumpy.
The Nifty was near flat at 0.05%, so this was stock-specific rather than market-wide. The honest reading: a recent earnings-call report is the only plausible trigger the data offers, and it is a secondary source rather than a filing. What the evidence does establish is the shape of the day — a large gap up, enormous turnover, and steady selling into it.
The numbers
- Last price ₹21,543.00, +7.95% on the day
- Day range ₹21,000.00 – ₹22,490.00
- Opening gap +9.24%
- NIFTY moved +0.05% the same session
Signals that fired
- Volume spike 30.7x
- Gap-and-hold +9.2%
- Below VWAP -0.59%
Technical context
Volume ran at 27.0× its 20-day average; rsi(14) sits at 73; price is 4.2% from the 52-week high; trading above the 50-dma and 200-dma.
Recent headlines
- Neuland Laboratories Ltd (BOM:524558) (Q1 2027) Earnings Call Highlights: Revenue Surges 116% ... — GuruFocus.com (15h ago)
- Neuland Laboratories Ltd. Revenue Breakdown – NSE:NEULANDLAB — TradingView (12d ago)
- NEULANDLAB Forecast — Price Target — Prediction for 2027 — TradingView (41d ago)
- Validation to velocity: Japan’s pharma model comes under execution pressure — Pharmaceutical Technology (70d ago)
- LIR Life Sciences Announces Start of Phase 1 of Transdermal Delivery Development Activities — MT Newswires (72d ago)
- Neuland Laboratories Ltd (BOM:524558) Q4 2026 Earnings Call Highlights: Robust Revenue Growth ... — GuruFocus.com (84d ago)
- Neuland Laboratories shares gain nearly 8% after a strong Q4 but Co warns of 'lumpy' numbers — CNBC TV18 (85d ago)
- Mukul Agrawal's top holdings: Nuvama, J&K Bank, Radico, Neuland & more — Should you buy? — Business Today (85d ago)
Sources
- Neuland Laboratories Ltd (BOM:524558) (Q1 2027) Earnings Call Highlights: Revenue Surges 116% ... — GuruFocus.com
- Neuland Laboratories Ltd. Revenue Breakdown – NSE:NEULANDLAB — TradingView
- NEULANDLAB Forecast — Price Target — Prediction for 2027 — TradingView
- Validation to velocity: Japan’s pharma model comes under execution pressure — Pharmaceutical Technology
- LIR Life Sciences Announces Start of Phase 1 of Transdermal Delivery Development Activities — MT Newswires
- Neuland Laboratories Ltd (BOM:524558) Q4 2026 Earnings Call Highlights: Robust Revenue Growth ... — GuruFocus.com
- Neuland Laboratories shares gain nearly 8% after a strong Q4 but Co warns of 'lumpy' numbers — CNBC TV18
- Mukul Agrawal's top holdings: Nuvama, J&K Bank, Radico, Neuland & more — Should you buy? — Business Today
Keep digging
- NEULANDLAB — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.